Key Points
- Director John Kiely sold 50,000 Amneal shares at an average price of $17.64, generating $882,000 and reducing his stake by 19.21% to 210,252 shares.
- Amneal shares opened at $18.15 and were trading up 5.1%, with a market capitalization of approximately $5.8 billion and a 52-week range of $9.20 to $19.26.
- Analysts maintain a favorable outlook, with a consensus “Buy” rating and an average price target of $17.67; several firms recently upgraded ratings or raised targets.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director John Kiely sold 50,000 shares of the firm's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares of the company's stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Amneal Pharmaceuticals Trading Up 5.1%
NASDAQ:AMRX opened at $18.15 on Friday. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.20 and a 52-week high of $19.26. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The stock has a fifty day simple moving average of $17.24 and a 200-day simple moving average of $14.59. The company has a market capitalization of $5.80 billion, a PE ratio of 37.04 and a beta of 1.27.
Wall Street Analyst Weigh In
AMRX has been the topic of several analyst reports. Zacks Research upgraded Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Friday, August 7th. The Goldman Sachs Group reiterated a "buy" rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. UBS Group lifted their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Finally, Barclays upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $17.67.
Get Our Latest Analysis on AMRX
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMRX. Rubric Capital Management LP increased its stake in Amneal Pharmaceuticals by 5.3% during the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company's stock worth $123,473,000 after acquiring an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Amneal Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company's stock worth $70,723,000 after purchasing an additional 81,546 shares in the last quarter. Morgan Stanley raised its holdings in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company's stock valued at $60,708,000 after buying an additional 1,315,018 shares during the period. Nantahala Capital Management LLC lifted its position in Amneal Pharmaceuticals by 14.7% during the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company's stock valued at $35,333,000 after buying an additional 558,877 shares in the last quarter. Finally, State Street Corp grew its stake in Amneal Pharmaceuticals by 3.4% during the fourth quarter. State Street Corp now owns 4,110,410 shares of the company's stock worth $51,791,000 after buying an additional 136,662 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.
About Amneal Pharmaceuticals
(
Get Free Report)
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
